NEW PRODUCT OF THE YEAR – AS VOTED BY VETS IN PRACTICE !* Have you used Senvelgo ® yet ?
A convenient , once-daily , oral solution for diabetes
Senvelgo ®’ s novel approach means you can now treat diabetes without injecting insulin
Simple dosing according to bodyweight No risk of clinical hypoglycaemia Glycaemic control can be achieved within a week 1 , 2
Make Senvelgo ® your new , simple solution for diabetic cats and their owners
Scan to learn more
* VMA Awards 2024
1 . Niessen , S . J . M . et al . ( 2022 ) Once daily oral therapy for feline diabetes mellitus : evaluation of SGLT-2 inhibitor velagliflozin as stand-alone therapy compared to insulin injection therapy in diabetic cats . Journal of Veterinary Internal Medicine 36 , 2512 – 2513 .
2 . Sparkes , A . H . et al . ( 2015 ) ISFM Consensus Guidelines on the Practical Management of Diabetes Mellitus in Cats . J Feline Med Surg 17 , 235 – 50 .
Senvelgo ® contains velagliflozin ( sodium-glucose co-transporter 2 [ SGLT-2 ] inhibitor ). UK ( GB ): POM-V . Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd ., RG12 8YS , UK . UK ( GB ) Tel : 01344 746959 ( sales ) or 01344 746957 ( technical ). Email : vetenquiries @ boehringer-ingelheim . com .
Volume 39 ( 4 ) • August 2024
Senvelgo ® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH , used under licence . © 2024 Boehringer Ingelheim Animal Health UK Ltd . All rights reserved . Date of preparation : May 2024 . UI-PET-0102-2024 . Use Medicines Responsibly .
33